Who
Bruce Polsky
Director
Company insider
Files Form 4 as: Director, Atea Pharmaceuticals; Director, Vision Sciences Inc /de/.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $61K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 20 Jun 2011
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,200 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —29,600 at $0.00 | filing |
| 21 Jun 2024filed 21 Jun 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,600 at $0.00 | filing |
| 21 Jun 2024filed 21 Jun 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,200 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $61K17,544 at $3.49 | filing |
| 16 Jun 2024filed 18 Jun 2024 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,150 at $0.00 | filing |
| 16 Jun 2024filed 18 Jun 2024 | AVIR Atea PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —33,150 at $0.00 | filing |
| 16 Jun 2023filed 21 Jun 2023 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,150 at $0.00 | filing |
| 16 Jun 2023filed 21 Jun 2023 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,750 at $0.00 | filing |
| 17 Jun 2022filed 21 Jun 2022 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —61,264 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.